FDA OKs Implant for Diabetic Eye Disease
The 0.7-mg dexamethasone implant (Ozurdex), made by Allergan, comes in a sustained-release biodegradable solid polymer delivery system. The agency approved it today for use in DME patients who have an artificial lens implant (pseudophakic) or who are awaiting surgery (phakic).
The mainstay of DME treatment has been laser photocoagulation of the retina, but the FDA approved a vascular endothelial growth factor (VEGF) inhibitor, ranibizumab (Lucentis), in 2012.
Since the VEGF inhibitor was approved for other eye-related diseases such as age-related macular degeneration (AMD) prior to that time, however, clinicians had been using the less expensive version, bevacizumab (Avastin), off-label for DME…..
Source: Med Page Today